Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1602605

registered interest
date	08/03/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Voluntary Scheme for Branded Medicines Pricing and Access: Life Sciences
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government, further to the Written Answer by Lord Markham of 14 February (HL5163), whether they will undertake a comparison of the impact of the UK's rebate rates in the voluntary scheme for branded medicines with the more favourable rebates in other European countries, given their declared ambitions for the UK life sciences sector.
tabling member printed	Lord Warner
uin	HL6286
answer	answer is ministerial correction date of answer 03/04/2023 answer text <p>We have no plans to undertake such a comparison. Differences in the structure of medicine pricing policies and systems make direct comparisons of payment percentages or rebates with other countries difficult and potentially misleading.</p><p> </p><p>The Government is open to ideas about how a successor to the voluntary scheme for branded medicines pricing and access should operate from 2024 onwards. We will be considering a range of factors and will work with industry to consider learning from approaches in the United Kingdom and internationally, to agree a mutually beneficial successor that supports better patient outcomes; ensures the sustainability of National Health Service spend on branded medicines; and enables a strong UK life sciences industry.</p> answering member printed Lord Markham question first answered 03/04/2023 11:31:55 answering member 4948 label Biography information for Lord Markham
tabling member	1732 label Biography information for Lord Warner

1601503

registered interest
date	06/03/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Integrated Care Systems: Finance
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government which Integrated Care Systems are forecast to be in debt at the end of the 2022–23 financial year.
tabling member printed	Baroness Merron
uin	HL6157
answer	answer is ministerial correction date of answer 17/04/2023 answer text <p>The 2022/23 year-end debt position of each individual organisation in the National Health Service will be confirmed in their individual balance sheets included in their accounts due to be published later this year. The Department does not hold in-year reporting data on debt.</p><p>The 2023/24 forecast surplus/deficit position against budget for individual integrated care systems (ICSs) will be agreed as part of the operational planning process between NHS England and ICSs which is currently ongoing. Draft plans are being resubmitted to NHS England and will be shared with the Department when they are finalised. We therefore do not currently have the information to show whether any ICS is planning to end 2023/24 with a deficit against their agreed budget.</p> answering member printed Lord Markham grouped question UIN HL6158 question first answered 17/04/2023 13:50:05 answering member 4948 label Biography information for Lord Markham
tabling member	347 label Biography information for Baroness Merron

1601505

registered interest
date	06/03/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Integrated Care Systems: Finance
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government which Integrated Care Systems have submitted draft operating plans forecasting that they will have no deficit at the end of the 2023–24 financial year.
tabling member printed	Baroness Merron
uin	HL6158
answer	answer is ministerial correction date of answer 17/04/2023 answer text <p>The 2022/23 year-end debt position of each individual organisation in the National Health Service will be confirmed in their individual balance sheets included in their accounts due to be published later this year. The Department does not hold in-year reporting data on debt.</p><p>The 2023/24 forecast surplus/deficit position against budget for individual integrated care systems (ICSs) will be agreed as part of the operational planning process between NHS England and ICSs which is currently ongoing. Draft plans are being resubmitted to NHS England and will be shared with the Department when they are finalised. We therefore do not currently have the information to show whether any ICS is planning to end 2023/24 with a deficit against their agreed budget.</p> answering member printed Lord Markham grouped question UIN HL6157 question first answered 17/04/2023 13:50:05 answering member 4948 label Biography information for Lord Markham
tabling member	347 label Biography information for Baroness Merron

1600603

registered interest
date	01/03/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Integrated Care Boards: Pay
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government, further to the Written Answer by Lord Markham on 7 February (HL4741), what criteria they used to decide whether to approve the salaries for Integrated Care Boards (ICB) Chief Executives in (1) Humber Coast and Vale, (2) South Yorkshire and Bassetlaw, and (3) Cornwall and Isles of Scilly; and why these Chief Executives were thought to justify higher salaries than other ICB Chief Executives.
tabling member printed	Lord Scriven
uin	HL6059
answer	answer is ministerial correction date of answer 03/04/2023 answer text <p>The criteria, as per the agreed pay framework, used to approve the salaries for the aforementioned integrated care board Chief Executives were geographical scale and complexity; stakeholder footprint and complexity; and systems complexity, including where any associated trusts are in financial and quality special measures. For these three chief executive roles these attributes were judged to be of an exceptional nature and, therefore, higher rates of pay were supported by Ministers.</p> answering member printed Lord Markham question first answered 03/04/2023 11:43:45 answering member 4948 label Biography information for Lord Markham
tabling member	4333 label Biography information for Lord Scriven

1599737

registered interest
date	27/02/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Tixagevimab/cilgavimab
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government, further to the Written Answer by Lord Markham on 7 February (HL4942) which confirmed that the expert working group established specifically to review Evusheld pre-exposure prophylaxis only met twice, the last meeting being on 19 May 2022, why the parliamentary Written Answers provided from that date until 4 July 2022 refer to asking clinicians to advise on the most appropriate option; and what other advice was being received during this period.
tabling member printed	Lord Mendelsohn
uin	HL5936
answer	answer is ministerial correction date of answer 05/04/2023 answer text <p>The National Expert Working Group is one of the sources of clinical opinion to develop clinical policies. During this period the RAPID C-19 cross-agency group was also set up to review COVID-19 therapies in response to the pandemic. They would consider evidence and analysis from a number of sources, including the Prophylaxis Oversight Group and the UK Health Security Agency. In addition, the Therapeutics Clinical Review Panel considered evidence for COVID-19 risk to help prioritise cohorts for prophylaxis. This informed thinking within the Department and was subsequently shared with the National Institute for Health and Care Excellence. These groups continued to consider emerging evidence, including published evidence from independent researchers and evidence from the company, after the last meeting of the Expert Working Group.</p> answering member printed Lord Markham question first answered 05/04/2023 14:48:03 answering member 4948 label Biography information for Lord Markham
tabling member	4286 label Biography information for Lord Mendelsohn